ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA has accepted the filing of Telix Pharmaceuticals Limited’s New Drug Application for TLX007-CDx, a new and proprietary cold kit for the preparation of PSMA-PET imaging for prostate cancer.

July 26, 2024

Vol.50 No.30

Drugs & Targets

FDA clears IND for Zymeworks’ antibody drug conjugate ZW191

FDA cleared the investigational new drug application for ZW191, a novel folate receptor-α targeted topoisomerase I inhibitor antibody-drug conjugate sponsored by Zymeworks.

July 26, 2024

Vol.50 No.30

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

More than a year after a catastrophic shortage of platinum-based chemotherapy drugs swept through the U.S., FDA on June 28 officially removed carboplatin and cisplatin from the drug shortage list.

Exscientia builds AWS AI-powered platform to advance drug discovery

Exscientia plc announced it will be expanding its work with Amazon Web Services to use the cloud provider’s artificial intelligence and machine learning services to power its platform for end-to-end drug discovery and automation.

July 12, 2024

Vol.50 No.28

Drugs & Targets

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

FDA granted Fast Track designation for Ac-FL-020, a radiopharmaceutical which targets prostate-specific membrane antigen for the treatment of metastatic castration-resistant prostate cancer.xxx:more

July 12, 2024

Vol.50 No.28

Drugs & Targets

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Boehringer Ingelheim and OSE Immunotherapeutics SA, a clinical-stage biotech company, announced that Boehringer will be progressing their first-in-class SIRPα immuno-oncology program into the next phase in clinical development.

July 12, 2024

Vol.50 No.28

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

YOU MAY BE INTERESTED IN

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA clears IND for Zymeworks’ antibody drug conjugate ZW191

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Exscientia builds AWS AI-powered platform to advance drug discovery

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Renew today!

Subscriber content

Login

ODAC vote will likely lead to three-arm and four-arm designs–and pragmatic trials–for perioperative indications

YOU MAY BE INTERESTED IN

FDA accepts Telix’s NDA for prostate cancer imaging agent

FDA clears IND for Zymeworks’ antibody drug conjugate ZW191

Platinum drugs are off the shortage list, but the underlying problem is unsolvedFDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”

Exscientia builds AWS AI-powered platform to advance drug discovery

FDA grants Fast Track designation to 225Ac-FL-020 radiopharmaceutical for mCRPC

Boehringer Ingelheim, OSE Immunotherapeutics collaborate to advance clinical development of SIRP immuno-oncology program

Login

Platinum drugs are off the shortage list, but the underlying problem is unsolved
FDA’s Califf: “We have a market failure due to unwillingness of health systems and cancer centers to pay a fair price.”